1. Academic Validation
  2. Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists

Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists

  • Bioorg Med Chem Lett. 2024 Nov 1:112:129944. doi: 10.1016/j.bmcl.2024.129944.
Donnette D Staas 1 Ian M Bell 2 Christopher S Burgey 1 James Z Deng 1 Steven N Gallicchio 1 John J Lim 1 Daniel V Paone 1 Craig M Potteiger 1 Anthony W Shaw 1 Heather Stevenson 1 Craig A Stump 1 C Blair Zartman 1 Eric L Moore 3 Joseph G Bruno 4 Scott D Mosser 4 Rebecca B White 5 Stefanie A Kane 3 Christopher A Salvatore 3 Samuel L Graham 1 Theresa M Williams 1 Harold G Selnick 1 Mark E Fraley 1
Affiliations

Affiliations

  • 1 Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA.
  • 2 Department of Discovery Chemistry, Merck & Co., Inc., West Point, PA 19486, USA. Electronic address: ian_bell@merck.com.
  • 3 Department of Neuroscience, Merck & Co., Inc., West Point, PA 19486, USA.
  • 4 Department of In Vitro Pharmacology, Merck & Co., Inc., West Point, PA 19486, USA.
  • 5 Department of Drug Metabolism & Pharmacokinetics, Merck & Co., Inc., West Point, PA 19486, USA.
Abstract

A novel series of 3-amino-piperidin-2-one-based Calcitonin gene-related peptide (CGRP) receptor antagonists was invented based upon the discovery of unexpected structure-activity observations. Initial exploration of the structure-activity relationships enabled the generation of a moderately potent lead structure (4). A series of modifications, including ring contraction and inversion of stereocenters, led to surprising improvements in CGRP Receptor affinity. These studies identified compound 23, a structurally novel potent, orally bioavailable CGRP Receptor Antagonist.

Keywords

CGRP receptor antagonist; Calcitonin gene-related peptide; Migraine.

Figures
Products